Ribometrix
Ribometrix is developing a new class of small-molecule therapeutics that directly target and modulate the function of RNA to treat human diseases.
Total Equity Investment: $45M+
Alert Banner
Alert:Watch the Boston Globe Today’s video on why North Carolina is an attractive place to grow a life sciences business, including lower business costs and highly skilled workforce.
Close Search Window
